95.47
price down icon6.00%   -6.09
pre-market  Pre-market:  95.90   0.43   +0.45%
loading
Abbott Laboratories stock is traded at $95.47, with a volume of 27.72M. It is down -6.00% in the last 24 hours and down -13.17% over the past month. Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$101.56
Open:
$97.13
24h Volume:
27.72M
Relative Volume:
2.34
Market Cap:
$165.90B
Revenue:
$44.33B
Net Income/Loss:
$6.50B
P/E Ratio:
25.68
EPS:
3.717
Net Cash Flow:
$7.40B
1W Performance:
-7.06%
1M Performance:
-13.17%
6M Performance:
-25.20%
1Y Performance:
-26.39%
1-Day Range:
Value
$93.92
$99.00
1-Week Range:
Value
$93.92
$102.77
52-Week Range:
Value
$93.92
$139.06

Abbott Laboratories Stock (ABT) Company Profile

Name
Name
Abbott Laboratories
Name
Phone
(224) 667-6100
Name
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Name
Employee
115,000
Name
Twitter
@AbbottNews
Name
Next Earnings Date
2026-04-16
Name
Latest SEC Filings
Name
ABT's Discussions on Twitter

Compare ABT vs SYK, MDT, BSX, EW

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ABT icon
ABT
Abbott Laboratories
95.47 176.48B 44.33B 6.50B 7.40B 3.717
SYK icon
SYK
Stryker Corp
338.38 130.69B 25.12B 3.25B 4.28B 8.3984
MDT icon
MDT
Medtronic Plc
85.65 111.83B 35.48B 4.64B 5.41B 3.582
BSX icon
BSX
Boston Scientific Corp
63.42 96.02B 20.08B 2.89B 3.66B 1.9391
EW icon
EW
Edwards Lifesciences Corp
79.05 45.09B 6.07B 1.06B 1.34B 1.8063

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-10-25 Initiated The Benchmark Company Buy
Jul-18-25 Upgrade Jefferies Hold → Buy
Jun-16-25 Initiated Leerink Partners Market Perform
Oct-08-24 Initiated Oppenheimer Outperform
Sep-19-24 Initiated Piper Sandler Overweight
Jul-30-24 Downgrade Edward Jones Buy → Hold
May-30-24 Initiated Goldman Buy
Jul-21-23 Upgrade Wolfe Research Underperform → Peer Perform
May-30-23 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-20-23 Reiterated Barclays Overweight
Apr-20-23 Reiterated Bernstein Outperform
Apr-20-23 Reiterated JP Morgan Overweight
Apr-20-23 Reiterated Raymond James Outperform
Apr-20-23 Reiterated UBS Buy
Apr-20-23 Reiterated Wolfe Research Underperform
Mar-29-23 Initiated UBS Buy
Oct-26-22 Initiated Mizuho Neutral
Oct-18-22 Initiated Barclays Overweight
Oct-12-22 Initiated Jefferies Hold
Jul-06-22 Initiated Wolfe Research Underperform
Mar-02-22 Resumed BofA Securities Buy
Jan-27-22 Reiterated Credit Suisse Outperform
Jan-27-22 Reiterated Morgan Stanley Overweight
Jan-27-22 Reiterated Raymond James Outperform
Jan-27-22 Reiterated UBS Buy
Dec-10-21 Initiated RBC Capital Mkts Outperform
Oct-27-21 Upgrade Atlantic Equities Neutral → Overweight
Oct-14-21 Initiated Redburn Neutral
May-25-21 Initiated Barclays Overweight
Apr-15-21 Initiated Atlantic Equities Neutral
Jan-28-21 Upgrade BTIG Research Neutral → Buy
Sep-11-20 Initiated Wolfe Research Outperform
Jun-01-20 Downgrade Goldman Neutral → Sell
Mar-05-20 Initiated Citigroup Buy
Feb-13-20 Initiated Goldman Neutral
Feb-06-20 Resumed BTIG Research Neutral
Jan-02-20 Downgrade Guggenheim Buy → Neutral
Jun-13-19 Reiterated BofA/Merrill Buy
Feb-07-19 Reiterated BofA/Merrill Buy
Jan-02-19 Downgrade Citigroup Neutral → Sell
Nov-30-18 Upgrade Goldman Neutral → Buy
Oct-16-18 Initiated Barclays Overweight
Jun-27-18 Initiated Bernstein Outperform
Jan-30-18 Reiterated Citigroup Neutral
Jan-25-18 Reiterated Stifel Buy
Jan-25-18 Upgrade William Blair Mkt Perform → Outperform
Jan-03-18 Initiated Evercore ISI Outperform
Jan-02-18 Upgrade JP Morgan Neutral → Overweight
Jan-02-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-19-17 Reiterated RBC Capital Mkts Outperform
Oct-19-17 Reiterated Stifel Buy
View All

Abbott Laboratories Stock (ABT) Latest News

pulisher
02:58 AM

Abbott Laboratories (ABT) Q1 2026 Earnings Call Highlights: Strong Medical Devices Growth Amid ... By GuruFocus - Investing.com Canada

02:58 AM
pulisher
01:45 AM

Inside Biotech: Abbott’s solid quarter isn’t enough as $21B bet rattles investors - Proactive financial news

01:45 AM
pulisher
Apr 16, 2026

Flu Season Fades, Abbott Stumbles: Is the 54-Year Dividend King Still Worth the Crown? - NAI500

Apr 16, 2026
pulisher
Apr 16, 2026

New cancer diagnostics and product updates see Abbott Laboratories stock fall amid oversold technicals - Traders Union

Apr 16, 2026
pulisher
Apr 16, 2026

Why Abbott Laboratories Stock Tumbled on Thursday - The Motley Fool

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Laboratories Bets on Devices in 2026 Call - TipRanks

Apr 16, 2026
pulisher
Apr 16, 2026

Why Abbott Laboratories Stock Tumbled on Thursday - The Motley Fool

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Laboratories (ABT) Lowers Earnings Outlook Amid Acquisiti - GuruFocus

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Laboratories (ABT) Shares Fall 6.0% -- What GF Score of 8 - GuruFocus

Apr 16, 2026
pulisher
Apr 16, 2026

Is Abbott Laboratories (ABT) Now Offering Value After A 20% Share Price Slide? - simplywall.st

Apr 16, 2026
pulisher
Apr 16, 2026

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix - WSJ

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott stock tumbles on earnings. Nutrition business is struggling and merger costs biting. - MSN

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Laboratories Slammed On Its Post-Exact Sciences Guidance - Investor's Business Daily

Apr 16, 2026
pulisher
Apr 16, 2026

These Stocks Are Today’s Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More - Barron's

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott trims 2026 profit forecast on Exact deal hit, shares fall - Reuters

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Laboratories (ABT) Reports Q1 2026 Earnings with Mixed Re - GuruFocus

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Laboratories (ABT) Reports Q1 2026 Earnings, Adjusts Fore - GuruFocus

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Laboratories (ABT) Faces Investor Concerns After Earnings Update - GuruFocus

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott stock slips on guidance cut, ranks 10th in healthcare equipment Quant ratings (ABT:NYSE) - Seeking Alpha

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott cuts profit forecast in wake of Exact Sciences deal - Modern Healthcare

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Stock Falls Despite Q1 Earnings & Revenue Beat - Yahoo Finance

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Laboratories: This Dividend Growth King Has Rarely Been So Cheap (NYSE:ABT) - Seeking Alpha

Apr 16, 2026
pulisher
Apr 16, 2026

Stocks making the biggest moves midday: Abbott Labs, AMD, Charles Schwab, On Semi & more - CNBC

Apr 16, 2026
pulisher
Apr 16, 2026

Leerink reiterates Abbott Labs stock rating at Market Perform By Investing.com - Investing.com India

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Laboratories Q1 2026 Earnings Call Summary - Yahoo Finance

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Laboratories (ABT) Reports Q1 Earnings In-Line with Expec - GuruFocus

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott cuts earnings outlook to reflect Exact Sciences buyout - MSN

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott lowers earnings forecast after $21B Exact Sciences buy - MedTech Dive

Apr 16, 2026
pulisher
Apr 16, 2026

Health Care ETFs take notice as Abbott Laboratories slides on earnings - Seeking Alpha

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Labs Reports Strong Q1 but Lowers EPS Guidance for 2026 - GuruFocus

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Laboratories (ABL.DE) Drops 4.7% on XETRA After Earnings - Meyka

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott defeats lawsuit alleging Similac contaminated by heavy metals - Reuters

Apr 16, 2026
pulisher
Apr 16, 2026

ABBV: Abbott Laboratories Reports In-Line EPS and Strong Revenue Beat - GuruFocus

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Laboratories (ABT) Forecasts Neutral FX Impact on Q2 Reve - GuruFocus

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott (ABT) Maintains Revenue Growth Outlook Amidst Adjustments - GuruFocus

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Laboratories (NYSE:ABT) Hits New 12-Month LowShould You Sell? - MarketBeat

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott (ABT.US) 1Q Adjusted EPS Beats; Nutrition Business Remains Weak - AASTOCKS.com

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott (ABT) Q1 2026 Earnings Call Transcript - The Motley Fool

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Laboratories Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales - WSJ

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Laboratories Q1 Earnings Call Highlights - MarketBeat

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott cuts profit forecast in wake of cancer screening deal - Crain's Chicago Business

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag - Proactive financial news

Apr 16, 2026
pulisher
Apr 16, 2026

Earnings call transcript: Abbott Labs Q1 2026 results align with expectations - Investing.com India

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Laboratories (ABT) Lowers Earnings Outlook Despite Revenue Growth - GuruFocus

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Earnings Beat Estimates. Why the Stock Is Slumping. - Barron's

Apr 16, 2026
pulisher
Apr 16, 2026

Market movers: Hims & Hers, Abbott Laboratories, QVC… - Proactive financial news

Apr 16, 2026
pulisher
Apr 16, 2026

Transcript: Abbott Laboratories Q1 2026 Earnings Conference CallAbbott Laboratories (NYSE:ABT) - Benzinga

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Cuts 2026 Earnings Outlook Following First-Quarter Beat - marketscreener.com

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Cuts Profit Forecast in Wake of Cancer Screening Deal - Bloomberg.com

Apr 16, 2026
pulisher
Apr 16, 2026

Abbott Laboratories Stock (ABT) Opened Down by 4.34% on Apr 16: What Investors Need To Know - TradingKey

Apr 16, 2026

Abbott Laboratories Stock (ABT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
SYK SYK
$338.38
price down icon 0.84%
MDT MDT
$85.65
price down icon 1.66%
BSX BSX
$63.42
price down icon 1.84%
EW EW
$79.05
price up icon 1.09%
$73.20
price down icon 0.42%
Cap:     |  Volume (24h):